These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 15568033)

  • 1. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection.
    Lu W; Arraes LC; Ferreira WT; Andrieu JM
    Nat Med; 2004 Dec; 10(12):1359-65. PubMed ID: 15568033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dendritic cell-based vaccine for treating HIV infection: background and preliminary results.
    Andrieu JM; Lu W
    J Intern Med; 2007 Feb; 261(2):123-31. PubMed ID: 17241177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD8+ T cells from most HIV-1-infected patients, even when challenged with mature dendritic cells, lack functional recall memory to HIV gag but not other viruses.
    Arrode G; Finke JS; Zebroski H; Siegal FP; Steinman RM
    Eur J Immunol; 2005 Jan; 35(1):159-70. PubMed ID: 15580653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection.
    García F; Lejeune M; Climent N; Gil C; Alcamí J; Morente V; Alós L; Ruiz A; Setoain J; Fumero E; Castro P; López A; Cruceta A; Piera C; Florence E; Pereira A; Libois A; González N; Guilá M; Caballero M; Lomeña F; Joseph J; Miró JM; Pumarola T; Plana M; Gatell JM; Gallart T
    J Infect Dis; 2005 May; 191(10):1680-5. PubMed ID: 15838795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of CD8+ T lymphocytes in chronic HIV-1 subtype A infection in Rwandan women.
    Jiang Y; Karita E; Castor D; Jolly PE
    Cell Mol Biol (Noisy-le-grand); 2005 Sep; 51 Suppl():OL737-43. PubMed ID: 16171573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of cytomegalovirus (CMV)-specific T cells in HIV-1-infected individuals progressing to AIDS with CMV end-organ disease.
    Bronke C; Palmer NM; Jansen CA; Westerlaken GH; Polstra AM; Reiss P; Bakker M; Miedema F; Tesselaar K; van Baarle D
    J Infect Dis; 2005 Mar; 191(6):873-80. PubMed ID: 15717261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization with an HIV-1 immunogen induces CD4+ and CD8+ HIV-1-specific polyfunctional responses in patients with chronic HIV-1 infection receiving antiretroviral therapy.
    Valor L; Navarro J; Carbone J; Rodríguez-Sáinz C; Gil J; López F; Fernández-Cruz E;
    Vaccine; 2008 May; 26(22):2738-45. PubMed ID: 18433946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes.
    Kloverpris H; Karlsson I; Bonde J; Thorn M; Vinner L; Pedersen AE; Hentze JL; Andresen BS; Svane IM; Gerstoft J; Kronborg G; Fomsgaard A
    AIDS; 2009 Jul; 23(11):1329-40. PubMed ID: 19528789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD8+ T cell responses to human immunodeficiency viruses type 2 (HIV-2) and type 1 (HIV-1) gag proteins are distinguishable by magnitude and breadth but not cellular phenotype.
    Gillespie GM; Pinheiro S; Sayeid-Al-Jamee M; Alabi A; Kaye S; Sabally S; Sarge-Njie R; Njai H; Joof K; Jaye A; Whittle H; Rowland-Jones S; Dorrell L
    Eur J Immunol; 2005 May; 35(5):1445-53. PubMed ID: 15832290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of virus-specific CD8(+) effector T cells in the course of HIV-1 infection: longitudinal analyses in slow and rapid progressors.
    Jansen CA; Piriou E; Bronke C; Vingerhoed J; Kostense S; van Baarle D; Miedema F
    Clin Immunol; 2004 Dec; 113(3):299-309. PubMed ID: 15507395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic and functional characteristics of HIV-specific CD8 T cells and gag sequence variability after autologous dendritic cells based therapeutic vaccine.
    López A; van der Lubbe N; Sánchez-Palomino S; Arnedo M; Nomdedeu M; Castro P; Guilà M; Maleno MJ; García F; Gallart T; Gatell JM; Plana M
    Vaccine; 2009 Oct; 27(44):6166-78. PubMed ID: 19712765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy.
    Stone SF; Price P; French MA
    HIV Med; 2005 Jul; 6(4):278-83. PubMed ID: 16011533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial.
    Ide F; Nakamura T; Tomizawa M; Kawana-Tachikawa A; Odawara T; Hosoya N; Iwamoto A
    J Med Virol; 2006 Jun; 78(6):711-8. PubMed ID: 16628588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous aldrithiol-2-inactivated HIV-1 combined with polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapy.
    Miller E; Spadaccia M; Sabado R; Chertova E; Bess J; Trubey CM; Holman RM; Salazar A; Lifson J; Bhardwaj N
    Vaccine; 2015 Jan; 33(2):388-95. PubMed ID: 25444812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells.
    Marovich MA; Mascola JR; Eller MA; Louder MK; Caudrelier PA; El-Habib R; Ratto-Kim S; Cox JH; Currier JR; Levine BL; June CH; Bernstein WB; Robb ML; Schuler-Thurner B; Steinman RM; Birx DL; Schlesinger-Frankel S
    J Infect Dis; 2002 Nov; 186(9):1242-52. PubMed ID: 12402193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of HIV-1 epitopes that induce the synthesis of a R5 HIV-1 suppression factor by human CD4+ T cells isolated from HIV-1 immunized hu-PBL SCID mice.
    Yoshida A; Tanaka R; Kodama A; Yamamoto N; Ansari AA; Tanaka Y
    Clin Dev Immunol; 2005 Dec; 12(4):235-42. PubMed ID: 16584108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential immunogenicity of HIV-1 clade C proteins in eliciting CD8+ and CD4+ cell responses.
    Ramduth D; Chetty P; Mngquandaniso NC; Nene N; Harlow JD; Honeyborne I; Ntumba N; Gappoo S; Henry C; Jeena P; Addo MM; Altfeld M; Brander C; Day C; Coovadia H; Kiepiela P; Goulder P; Walker B
    J Infect Dis; 2005 Nov; 192(9):1588-96. PubMed ID: 16206073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine.
    Cobb A; Roberts LK; Palucka AK; Mead H; Montes M; Ranganathan R; Burkeholder S; Finholt JP; Blankenship D; King B; Sloan L; Harrod AC; Lévy Y; Banchereau J
    J Immunol Methods; 2011 Feb; 365(1-2):27-37. PubMed ID: 21093448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients.
    Lévy Y; Gahéry-Ségard H; Durier C; Lascaux AS; Goujard C; Meiffrédy V; Rouzioux C; El Habib R; Beumont-Mauviel M; Guillet JG; Delfraissy JF; Aboulker JP;
    AIDS; 2005 Feb; 19(3):279-86. PubMed ID: 15718838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
    Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
    Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.